Intuitive Surgical Inc. (NASDAQ: ISRG) posted second‑quarter 2026 results that beat analyst forecasts, yet its shares fell 10.9% after the company issued a weaker‑than‑expected outlook for 2026 da Vinci procedure growth. Adjusted earnings per share were $2.80, surpassing the consensus estimate of $2.51 by $0.29. Revenue reached $2.89 billion, a 19% increase year‑on‑year from $2.44 billion in the comparable quarter of 2025 and above the $2.82 billion analyst estimate. The quarter also included a $28 million after‑tax benefit, equivalent to $0.08 per share, arising from refunds of tariffs paid in prior periods.
The company projected full‑year 2026 da Vinci procedure growth of 13.5% to 15.5%, indicating that actual growth is expected to be nearer the midpoint of 14.5%. This guidance fell short of investor expectations and contributed to the 10.9% decline in the stock price. Adjusted gross profit margin is expected to be between 68.0% and 69.0% of revenue, which incorporates an estimated 1.0% impact from tariffs. Adjusted operating expenses are forecast to grow 11% to 13% year‑over‑year.
Worldwide procedures performed with the da Vinci and Ion platforms grew approximately 16% in the quarter; da Vinci procedures rose about 15% while Ion procedures surged roughly 36%. The company placed 468 da Vinci surgical systems during the quarter, up from 395 in the prior‑year period, including 246 units of the da Vinci 5 system. The installed base of da Vinci systems reached 11,710 units as of 30 June 2026, representing a 12% increase from 10,488 units a year earlier.
Revenue from instruments and accessories increased 18% to $1.73 billion, while systems revenue grew to $685 million from $575 million in the year‑ago quarter. “We are pleased with company performance this quarter, which reflects the strength of our portfolio – from da Vinci and Ion to our growing digital solutions,” said Dave Rosa, CEO of Intuitive Surgical.